Actinium Pharmaceuticals, INC

Actinium Pharmaceuticals has submitted a compliance plan to NYSE American to regain compliance with listing standards related to stockholder equity.

Actinium Pharmaceuticals has received a notice of non-compliance from the NYSE American regarding stockholders' equity requirements.

Actinium Pharmaceuticals, Inc. announced its board's decision to hold annual shareholder advisory votes on executive compensation, aligning with shareholder preference.

Actinium Pharmaceuticals announces the resignation of its Chief Financial Officer, Steve O'Loughlin, with CEO Sandesh Seth assuming the principal financial officer duties.

Actinium Pharmaceuticals, Inc. announced the re-election of Class III directors and the approval of all proposals at its 2025 annual meeting of stockholders.

Actinium Pharmaceuticals dismisses Marcum LLP as its independent auditor due to its acquisition by CBIZ CPAs, and subsequently engages CBIZ CPAs as its new auditor.

Actinium Pharmaceuticals reports reduced net loss in Q3 2025, driven by cost cuts, but faces significant cash burn, Iomab-B regulatory setbacks, and ongoing legal challenges.

Actinium Pharmaceuticals reports increased net loss for H1 2025, a strategic pivot to solid tumor therapies, and ongoing legal challenges.

Actinium Pharmaceuticals reports its Q1 2025 financial results and provides an update on its clinical development programs, including Actimab-A, Iomab-ACT, and ATNM-400.

Actinium Pharmaceuticals' Q3 2024 report details financial results and provides updates on the clinical development of Iomab-B, Actimab-A, and Iomab-ACT, including regulatory feedback and strategic partnership efforts.

Actinium Pharmaceuticals reported its second quarter 2024 financial results and provided an update on the regulatory pathway for its lead drug candidate, Iomab-B, noting the FDA requires an additional clinical trial.

Actinium Pharmaceuticals reported a net loss of $8.7 million for the first quarter of 2024, while progressing regulatory filings for Iomab-B and advancing its pipeline.

Actinium Pharmaceuticals' 2024 annual report details the company's financial results, pipeline advancements, and strategic focus on targeted radiotherapies for advanced cancers.

Actinium Pharmaceuticals' 2023 annual report details progress in clinical trials for Iomab-B and Actimab-A, along with financial updates and strategic priorities.

Actinium Pharmaceuticals CEO Sandesh Seth will dispose of 120,900 shares of common stock on August 18, 2025, to cover tax obligations from RSU vesting.

Richard I. Steinhart, a director at Actinium Pharmaceuticals, canceled several stock options effective March 31, 2025.

Jeffrey W. Chell, a director at Actinium Pharmaceuticals, canceled several stock options on March 31, 2025, as per an Option Cancellation and Release Agreement.

Director June Sherie Almenoff cancels stock options to purchase 50,000 shares of Actinium Pharmaceuticals common stock effective March 31, 2025.

C. David Nicholson, a director at Actinium Pharmaceuticals, canceled several stock options effective March 31, 2025.

Director Ajit Shetty cancels multiple stock options in Actinium Pharmaceuticals, effective March 31, 2025, as per an Option Cancellation and Release Agreement.

Actinium Pharmaceuticals, Inc. announces its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and executive compensation advisory votes.

Actinium Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held on November 27, 2024, with proposals to elect directors and ratify the appointment of Marcum LLP as the independent auditor.

The Vanguard Group has reported a 4.39% beneficial ownership stake in Actinium Pharmaceuticals Inc., holding 1,371,840 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Actinium Pharmaceuticals, Inc. as of June 30, 2025.